Royalty Report: Biological Materials, Drugs, Chemicals – Collection: 299254

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Biological Materials
  • Drugs
  • Chemicals
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299254

License Grant
Licensor hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement a non-exclusive license to the Licensed Biological Materials to make and have made, to use and have used, to sell and have sold, to offer to sell and to import any Licensed Biological Materials in the Field and to create any progeny, mutant, or derivative work thereof. Except for the license and sub-license rights granted pursuant to this Agreement, Licensor shall not grant a license to the Licensed Biological Materials to any party except to other nonprofit or academic institutions (collectively, the “Research Institutions”) solely for research and educational use, provided that any such license to the Licensed Biological Materials granted to the Research Institutions shall prohibit the commercialization of such Licensed Biological Materials by such Research Institutions and shall not in any way limit Licensee’s commercialization rights under this Agreement.
License Property
The term Licensed Biological Materials shall mean the materials supplied by Licensor (identified in Agreement) together with any progeny, mutants, or derivatives thereof supplied by Licensor or created by Licensee. All Licensed Biological Materials shall be deemed Licensor’s Confidential Information whether or not marked as “confidential”.

Materials include but not limited to Hybridoma cell lines and AP haptens.

The term Licensed Patent Rights shall mean rights arising out of or resulting from (a) the U.S./PCT patent application(s) set forth in this Agreement; (b) the foreign patent applications associated with the application(s) referenced in sub clause (a) above; (c) the patents issued from the application(s) referenced in sub clauses (a) and (b); (d) divisionals, continuations, reissues, reexaminations, and extensions of any patent or application set forth in sub clauses (a)- (c) above; and (e) all claims of continuations-in-part that are entitled to the benefit of the priority date of the application(s) referenced in sub clause (a) above.

Licensed Patent Serial No.
60/982,593 – Antibody-Mediated Disruption of Quorum Sensing in Bacteria
WO 09/055054 – Antibody-Mediated Disruption of Quorum Sensing in Bacteria

The term Licensed Product shall mean any product (a) covered by a Valid Claim of the Licensed Patent Rights, or (b) that utilizes or incorporates Licensed Biological Materials.

Quorum sensing entails a process whereby bacteria, such as MRSA, secrete species-specific signaling peptides, which, once a critical concentration is reached, induce the activation of biological pathways employed by the respective bacteria, including ones involved in virulence. Using animal models and potentially lethal MRSA infections, researchers at TSRI have shown marked increases in survival by neutralizing these signaling peptides through immunotherapies using either monoclonal antibodies or vaccines.

Field of Use
The novel technology is based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA).

Staphylococcus aureus or “staph” is a type of bacteria found on human skin, in the nose, armpit, groin, and other areas. While these germs don't always cause harm, they can make you sick under the right circumstances.

Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by a type of staph bacteria that's become resistant to many of the antibiotics used to treat ordinary staph infections.

IPSCIO Record ID: 215178

License Grant
The Licensor grants an exclusive license under the licensed subject matter to manufacture, have manufactured, use, import, offer to sell and/or sell licensed products within licensed territory for use within the licensed field.
License Property
The product relates to the development of A Non-hazardous Peptide and Protein-Based Chemical/ Biological Decontamination System, also referred to as a Chemical Manufacturing Process – ALL Clear.

ALL-CLEARâ„¢ is a decontamination foam product.

U.S. Patent Application Serial No. 10/182,821, Canadian Patent Application Serial No. 2397075 and European Patent Application Serial Number EPO/01 918 985.1)

Field of Use
The licensed field means non-hazardous bio-decontamination by or through the use of an aqueous, sprayable foam.

ALL-CLEAR(TM) is intended for the non-hazardous and non-toxic neutralization and/or decontamination of biological pathogens and/or chemical agents. ALL-CLEAR(TM) has applications for eliminating biological and chemical warfare agents, treating industrial and infectious waste and decontaminating aircraft and vehicles arriving from quarantined areas, as well as agricultural applications such as treating livestock processing and control areas to destroy and prevent the spread of infectious diseases in animals.

IPSCIO Record ID: 280845

License Grant
This joint venture is for the purpose of collecting and analysing data relating to the genetics of Neuroticism and Associated Disorders.

The Australian Institute grants to the English Company (a) an exclusive and perpetual world-wide licence to use, publish, comment on, sub-licence, sell or otherwise deal in the Deliverables, and (b) an exclusive and a perpetual world-wide licence to use the Existing Biological Materials and the Biological Materials for the purpose of undertaking the genotyping as envisaged in the Research Project and otherwise for its own purposes provided that the Company may only use such materials for the purposes for which consent for use of the same was granted.

The Company grants to Institute a non-exclusive licence to the Ausagene Assets and to genotyping results referred to in this agreement for the sole purposes of undertaking the Research Project and conducting non-commercial research and publishing the results thereof as permitted in this Agreement.

License Property
Products means any Intellectual Property derived from the JVA which are specifically related to and designed for the preventive, or diagnostic or treatment of Anxiety or Neuroticism.

Associated Disorders- means Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) as defined by DSM IV criteria.

Ausagene Assets – means the data on Neuroticism and Associated Disorders on 599 sib-pairs acquired by the Company from Ausagene Inc. pursuant to a sale agreement dated of even date herewith and consented to in the Consent.

Biological Materials – blood, tissue or DNA samples generated pursuant to this Agreement.

Existing Biological Materials – means the blood samples collected by Institute on not less than 599 sib-pairs selected from the individuals upon whom data is comprised in the Ausagene Assets as being extremely discordant or concordant for the Phenotypes.

Phenotypes – refer to Neuroticism scores and Composite International Diagnostic Inventory (CIDI) assessments of related disorders as defined above.

Intellectual Property includes all copyright and all rights in relation to inventions, databases and all other rights resulting from intellectual activity pursuant to this Agreement including Know-how whether capable of protection by registration or otherwise under the laws of any country or not.

Joint Venture (abbreviated in thin Agreement to 'JV') means the joint undertaking of the parties hereto in finding and undertaking research for the purpose of identifying genes underlying the conditions, of Neuroticism and Associated Disorders in accordance with this Agreement, including the collective rights and obligations of all parties hereto.

Field of Use
This agreement pertains to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.